Estrella Financial Statements From 2010 to 2025

ESLAW Stock   0.08  0.03  22.82%   
Estrella Immunopharma financial statements provide useful quarterly and yearly information to potential Estrella Immunopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Estrella Immunopharma financial statements helps investors assess Estrella Immunopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Estrella Immunopharma's valuation are summarized below:
There are over sixty available fundamental signals for Estrella Immunopharma, which can be analyzed over time and compared to other ratios. All traders should should verify Estrella Immunopharma's prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable.
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 2 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.81. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out the analysis of Estrella Immunopharma Correlation against competitors.
For more information on how to buy Estrella Stock please use our How to Invest in Estrella Immunopharma guide.

Estrella Immunopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding16.4 M31.7 M30.1 M
Slightly volatile
Cash And Short Term InvestmentsM4.8 M3.8 M
Slightly volatile
Liabilities And Stockholders Equity5.2 MM5.2 M
Pretty Stable
Other Current Assets302.3 K259.9 K678.9 K
Slightly volatile
Other Stockholder Equity15.8 M27.3 M5.4 M
Slightly volatile
Non Current Liabilities Other11 K11.5 K14.1 K
Slightly volatile
Common StockK4.2 K583.7 K
Pretty Stable
Short and Long Term Debt Total398.9 K448.7 K489.3 K
Slightly volatile
Short Term Debt398.9 K448.7 K489.3 K
Slightly volatile
Net Receivables231 K259.9 K283.3 K
Slightly volatile

Estrella Immunopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization246.2 K262.8 K217 K
Slightly volatile
Selling General Administrative3.9 M3.7 M908 K
Slightly volatile
Other Operating Expenses8.8 M8.4 M2.2 M
Slightly volatile
Research Development3.4 M4.7 M1.6 M
Slightly volatile
Total Operating Expenses8.8 M8.4 M2.2 M
Slightly volatile
Total Other Income Expense Net836.7 K588.7 K1.2 M
Slightly volatile

Estrella Immunopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.4 M1.4 M320.8 K
Slightly volatile
Other Cashflows From Financing Activities15.9 M15.1 M3.6 M
Slightly volatile
Other Cashflows From Investing ActivitiesM4.5 M4.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables25.6 K27 K360.8 K
Slightly volatile
Cash Per Share0.00670.00710.5329
Slightly volatile
Income Quality1.01.04791.0129
Slightly volatile
Current Ratio0.04640.04895.4487
Very volatile
Graham Number1.472.18441.2171
Slightly volatile
Debt To Equity0.05640.06350.0692
Slightly volatile
Average Receivables115.5 K129.9 K141.7 K
Slightly volatile
Interest Debt Per Share0.06920.07790.0849
Slightly volatile
Debt To Assets0.03990.04490.049
Slightly volatile
Ebt Per Ebit0.460.520.5716
Slightly volatile
Total Debt To Capitalization0.05270.05930.0646
Slightly volatile
Debt Equity Ratio0.05640.06350.0692
Slightly volatile
Quick Ratio0.04640.04895.4487
Very volatile
Net Income Per E B T1.141.08811.0199
Slightly volatile
Cash Ratio0.03610.0384.6867
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9813
Slightly volatile
Debt Ratio0.03990.04490.049
Slightly volatile

Estrella Immunopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap53.9 M59.3 M42.2 M
Slightly volatile
Enterprise Value51.9 M59.8 M38.8 M
Slightly volatile

Estrella Fundamental Market Drivers

Cash And Short Term Investments4.2 M

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.